CMS Expands Medicare Coverage for Molecular Diagnostic Tests

CMS Expands Medicare Coverage for Molecular Diagnostic Tests

The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.

CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:

  • Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
  • Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)

The LCDs will take effect Aug. 17 in 23 states.

Source:

https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025

A logo with the letters 'HD' for 'HealthDay'

PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released

PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released

Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.

Read More
TELCOR Promotions - November 2026

TELCOR Promotions - November 2026

Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).

Read More
Recently Released CLFS Data Reveal Large Differences in Test Volume by Laboratory Setting

Recently Released CLFS Data Reveal Large Differences in Test Volume by Laboratory Setting

The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...

Read More